These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 26846335)

  • 41. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
    Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
    J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ATP-induced fibrogenic pathway in circulating cells obtained by idiopathic pulmonary fibrotic (IPF) patients is not blocked by nintedanib and pirfenidone.
    Colarusso C; Falanga A; Di Caprio S; Terlizzi M; D'Andria E; Antonio M; Maiolino P; Sorrentino R
    Biomed Pharmacother; 2024 Jul; 176():116896. PubMed ID: 38876049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
    Wongkarnjana A; Yanagihara T; Kolb MR
    Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
    [No Abstract]   [Full Text] [Related]  

  • 44. Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients.
    Fournier D; Jouneau S; Bouzillé G; Polard E; Osmont MN; Scailteux LM
    Pulm Pharmacol Ther; 2022 Oct; 76():102149. PubMed ID: 35918026
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
    Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
    Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
    Hayton C; Chaudhuri N
    Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia.
    Cox IA; de Graaff B; Corte TJ; Glaspole I; Chambers DC; Moodley Y; Teoh A; Walters EH; Palmer AJ
    Aust Health Rev; 2021 Dec; 45(6):718-727. PubMed ID: 34706811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
    Hisata S; Bando M; Homma S; Kataoka K; Ogura T; Izumi S; Sakamoto S; Watanabe K; Saito Y; Shimizu Y; Kato M; Nishioka Y; Hara H; Waseda Y; Tanino Y; Yatera K; Hashimoto S; Mukae H; Inase N;
    Respir Investig; 2021 Nov; 59(6):819-826. PubMed ID: 33994347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
    Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
    Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Idiopathic Pulmonary Fibrosis].
    Prasse A
    Pneumologie; 2015 Oct; 69(10):608-14; quiz 615. PubMed ID: 26444136
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro.
    Stahnke T; Kowtharapu BS; Stachs O; Schmitz KP; Wurm J; Wree A; Guthoff RF; Hovakimyan M
    PLoS One; 2017; 12(2):e0172592. PubMed ID: 28231275
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pirfenidone and nintedanib attenuates pulmonary artery endothelial and smooth muscle cells transformations induced by IL-11.
    Roger I; Montero P; Milara J; Cortijo J
    Eur J Pharmacol; 2024 Jun; 972():176547. PubMed ID: 38561103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An updated safety review of the drug treatments for idiopathic pulmonary fibrosis.
    Sgalla G; Comes A; Richeldi L
    Expert Opin Drug Saf; 2021 Sep; 20(9):1035-1048. PubMed ID: 33881959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
    Amati F; Stainer A; Polelli V; Mantero M; Gramegna A; Blasi F; Aliberti S
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175556
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
    Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
    Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
    Di Martino E; Provenzani A; Vitulo P; Polidori P
    Ann Pharmacother; 2021 Jun; 55(6):723-731. PubMed ID: 33054319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
    Maher TM; Strek ME
    Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies.
    Lunardi F; Pezzuto F; Vuljan SE; Calabrese F
    Arch Pathol Lab Med; 2018 Sep; 142(9):1090-1097. PubMed ID: 30141997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.